Vanguard Capital Management
ALNY icon

Vanguard Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vanguard Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82B Buy
6,029,478
+82,772
+1% +$25M 0.04% 351
2026
Q1 		$1.97B Buy
+5,946,706
New +$2.02B 0.05% 309

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management's ALNY Position: Q2 2026 in Review

Vanguard Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 1.4% in Q2 2026, buying an estimated $25M and bringing the position to 6,029,478 shares worth $1.82B. The position accounts for 0.04% of the portfolio, ranked #351.

Vanguard Capital Management first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.97B in Q1 2026. 733 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Vanguard Capital Management held 6,029,478 shares of Alnylam Pharmaceuticals worth $1.82B as of Q2 2026.
  • Vanguard Capital Management bought 82,772 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $25M.
  • Alnylam Pharmaceuticals made up 0.04% of Vanguard Capital Management's portfolio in Q2 2026, its #351 holding.
  • Vanguard Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Alnylam Pharmaceuticals position peaked at $1.97B in Q1 2026.
  • 733 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.